Signifor
NDC Package 0078-0633-20

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Signifor is pasireotide is used to treat a certain condition (Cushing's disease) when surgery has not been fully successful or cannot be used to correct the condition. Marketed by Novartis Pharmaceuticals Corporation, this product is identified by NDC 0078-0633 and is authorized under FDA application NDA200677.

Identification & Billing

NDC Package Code
0078-0633-20
Package Description
60 PACKAGE in 1 BOX / 6 AMPULE in 1 PACKAGE (0078-0633-06) / 1 mL in 1 AMPULE (0078-0633-61)
Product Code
11-Digit Billing Format
00078063320
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.

Clinical Specifications

Proprietary Name
Signifor
Dosage Form
-
Usage Information
Pasireotide is used to treat a certain condition (Cushing's disease) when surgery has not been fully successful or cannot be used to correct the condition. Cushing's disease occurs when the body makes too much of a certain hormone called cortisol. Having too much cortisol in the body may lead to high blood pressure, high blood sugar, and other problems. Pasireotide works by decreasing the amount of cortisol made in the body.

Regulatory & Marketing

Labeler Name
Novartis Pharmaceuticals Corporation
FDA Application #
NDA200677
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
12-14-2012
End Marketing Date
09-30-2022
Listing Expiration
09-30-2022
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0078-0633-20 identifies a specific commercial package of 60 package in 1 box / 6 ampule in 1 package (0078-0633-06) / 1 ml in 1 ampule (0078-0633-61) of Signifor, labeled by Novartis Pharmaceuticals Corporation. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Novartis Pharmaceuticals Corporation on December 14, 2012. The current certification is valid through September 30, 2022.

What are the primary indications for this medication?

Pasireotide is used to treat a certain condition (Cushing's disease) when surgery has not been fully successful or cannot be used to correct the condition. Cushing's disease occurs when the body makes too much of a certain hormone called cortisol. Having too much cortisol in the body may lead to high blood pressure, high blood sugar, and other problems. Pasireotide works by decreasing the amount of cortisol made in the body.

How is this Novartis Pharmaceuticals Corporation product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00078063320. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0078-0633-20
11-Digit CMS (5-4-2)
00078-0633-20

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.